Literature DB >> 11767116

Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism.

A Soyama1, Y Saito, N Hanioka, N Murayama, O Nakajima, N Katori, S Ishida, K Sai, S Ozawa, J I Sawada.   

Abstract

By sequencing genomic DNA from 73 established cell lines derived from Japanese individuals, we detected 9 single nucleotide polymorphisms (SNPs) in the CYP2C8 gene. Of them, 3 exonic SNPs resulted in amino acid alterations (g416a, R139K; a1196g, K399R; c1210g, P404A). The first two alterations were detected concurrently in one cell line and thought to be the same as CYP2C8*3. To examine the effects of these amino acid alterations on CYP2C8 function, wild-type and four types of variant CYP2C8 cDNA constructs (R139K, K399R, R139K/K399R and P404A) were transfected into Hep G2 cells and their paclitaxel 6a-hydroxylase activities were determined in vitro. Km values were not significantly different from that of the wild-type in any of the variants studied. The variant R139K/K399R showed reduced values for Vmax and clearance (Vmax/Km) similar to those of its single variant, R139K. The variant P404A also showed a significantly lowered clearance due to reduced level of protein expression. These results suggest that not only the double variant (R139K/K399R, CYP2C8*3) but also our novel variant P404A in the CYP2C8 gene are less efficient in paclitaxel metabolism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11767116     DOI: 10.1248/bpb.24.1427

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  20 in total

Review 1.  Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

2.  The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.

Authors:  Tanja Busk Bidstrup; Per Damkier; Anette Kristensen Olsen; Marianne Ekblom; Anders Karlsson; Kim Brøsen
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

3.  Genetic polymorphisms of CYP2C8 in the Czech Republic.

Authors:  Kristina Pechandova; Helena Buzkova; Olga Matouskova; Frantisek Perlik; Ondrej Slanar
Journal:  Genet Test Mol Biomarkers       Date:  2012-02-07

4.  Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5.

Authors:  Rüdiger Kaspera; Suresh B Naraharisetti; Eric A Evangelista; Kristin D Marciante; Bruce M Psaty; Rheem A Totah
Journal:  Biochem Pharmacol       Date:  2011-06-24       Impact factor: 5.858

5.  Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.

Authors:  Christina L Aquilante; Lisa A Kosmiski; David W A Bourne; Lane R Bushman; Elizabeth B Daily; Kyle P Hammond; Charles W Hopley; Rajendra S Kadam; Alexander T Kanack; Uday B Kompella; Merry Le; Julie A Predhomme; Joseph E Rower; Maha S Sidhom
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

Review 6.  Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals.

Authors:  Elena García-Martín; Carmen Martínez; José M Ladero; José A G Agúndez
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

Review 7.  Human pharmacogenomic variations and their implications for antifungal efficacy.

Authors:  Joseph Meletiadis; Stephen Chanock; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

8.  Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.

Authors:  Jatinder Kaur Lamba; Brooke L Fridley; Taraswi M Ghosh; Qing Yu; Gaurav Mehta; Pankaj Gupta
Journal:  Pharmacogenomics       Date:  2014       Impact factor: 2.533

9.  Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.

Authors:  Elizabeth B Daily; Christina L Aquilante
Journal:  Pharmacogenomics       Date:  2009-09       Impact factor: 2.533

10.  Global variation in CYP2C8-CYP2C9 functional haplotypes.

Authors:  William C Speed; Soonmo Peter Kang; David P Tuck; Lyndsay N Harris; Kenneth K Kidd
Journal:  Pharmacogenomics J       Date:  2009-04-21       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.